Genmab A (GMAB) Interest Expenses (2019 - 2026)

Genmab A has reported Interest Expenses for 5 years, with the latest figure at -$150.0 million in Q1 2026.

• For the quarter ending Q1 2026, Interest Expenses fell 233.33% year-over-year to -$150.0 million; the trailing twelve-month figure through Mar 2026 stood at -$278.0 million (down 44.79% YoY), and the FY2025 full-year result was $269.0 million, down 7.56% from the prior year.
• Interest Expenses for Q1 2026 stood at -$150.0 million, down from -$37.0 million in the prior quarter.
• The five-year high for Interest Expenses was -$35.0 million in Q1 2024, with the low at -$150.0 million in Q1 2026.
• Historically, Interest Expenses has averaged -$72.1 million across 3 years, with a median of -$46.0 million in 2024.
• Annual changes were most pronounced in 2025 — Interest Expenses soared 63.37% — and 2026, when it sank 233.33%.
• Genmab A's Interest Expenses stood at -$101.0 million in 2024, then soared by 63.37% to -$37.0 million in 2025, then tumbled by 305.41% to -$150.0 million in 2026.
• The last three Interest Expenses figures came in at -$150.0 million (Q1 2026), -$37.0 million (Q3 2025), and -$91.0 million (Q2 2025), per Business Quant data.